“the phase two CADANCE study exploring the potential in pulmonary hypertension due to left heart disease a specific segment within WHO group two, has completed recruitment and is on track for completion later this year.”

In context

“ate, the external steering committee determined that the Phase III Hyperion study had lost clinical equipoise and should also be stopped early. All participants have now been given the option to receive winravir. We anticipate sharing data from the Hyperion study later this year. The clinical benefit and statistically significant improvement observed across a range of patients receiving winravir in the STEALAR and ZENITH study provide strong evidence for its potential to be practice-changing and to alter the trajectory for patients with this devastating disease. The clinical program also includes the ongoing long-term extension study, Suteria, as well as the phase two light ray study, which is being conducted to support the development of an auto-injector option for patients. In addition, the phase two CADANCE study exploring the potential in pulmonary hypertension due to left heart disease a specific segment within WHO group two, has completed recruitment and is on track for completion later this year. We continue to bolster our portfolio of candidates targeting cardiometabolic disease. In March, we announced an exclusive license agreement with Hungry Pharma, for HRS five three four six an investigational oral small molecule lipoprotein a or LP little a formation inhibitor. Elevated levels of LP little a in the blood are an inherited atherosclerotic cardiovascular disease risk factor for which there are currently no approved treatment options. Hong Rui recently initiated a phase two clinical trial for HRS five three four six in China. We are planning a robust global clinical development program that expands and complements our broader cardiometabolic pipeline. Next to vaccines. We continue to secure regulatory approvals globally for Cavaxib. More recently, the European Commission grante”